The Danish Pharma Giant Shares Soar on Promising Anti-Obesity Pill Results
The valuation of the Denmark-based pharmaceutical firm climbed by more than £6.5bn after clinical trial results showed that its oral anti-obesity medication produced almost as much weight reduction as its injectable counterpart.
Stock in the drugmaker rose by over 4.5% on Thursday as investors grew optimistic about its potential to reclaim market share in the face of growing competition from competing firms and cheaper non-branded alternatives of GLP-1 drugs.
A recent clinical trial showed that a daily pill version of the company’s injectable treatment resulted in substantial reduction in body weight, with nearly 33% of trial subjects shedding at least a fifth of their body mass. Observed side effects were comparable to those of the injectable therapy.
This marks the first oral GLP-1 medication submitted to the FDA for review, and regulatory clearance is expected by the end of this year. Manufacturing has already begun at the firm’s American sites.
This progress puts the firm in direct competition with American competitor its industry counterpart, which is likewise working on a once-daily obesity treatment tablet known as orforglipron. Trial findings from the US company showed that one in five participants achieved at least one-fifth of their mass over a year-and-a-half timeframe.
While injectable treatments are enjoying broad acceptance, they are expensive and often subject to supply constraints. Pill forms are generally simpler to produce, store, and administer, and may potentially be sold at a more affordable price.
Market analysts suggest that oral anti-obesity drugs could generate annual revenues as high as ten billion dollars, with some projections pointing to a maximum potential of up to $25 billion.
Shares of firms specializing in weight management drugs have substantially beaten traditional pharmaceutical stocks over the past five years, highlighting strong market confidence in this growing industry.
